• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 11/5/24: FDA’s Diversity Action Plan Guidance, Combatting Medical Misinformation & more

News
Article

The latest news for pharma industry insiders.

A Strategic Look at FDA’s Diversity Action Plan Guidance

In a video interview with Applied Clinical Trials, Jay Park and Rebecca Metcalfe of Core Clinical Sciences discussed their recent article published in JAMA titled, “Diversity Action Plans in Clinical Trials.” In addition to key takeaways from the article, Park and Metcalfe discussed the FDA's new guidance for diversity action plans in clinical trials, the role of risk-based monitoring as a tool for improving diversity, and the importance of patient-reported outcomes.

Combatting Medical Misinformation: Strategies for Patient Education, Curriculum Integration, and Social Media Engagement

Pharmacy Times interviewed Julie Sibbesen, PharmD, a clinical pharmacy specialist in Enterprise Medication Use at WVU Medicine in Morgantown, West Virginia, on her presentation at the 2024 American College of Clinical Pharmacy Annual Meeting in Phoenix, Arizona, on strategies for pharmacists to effectively address and debunk medical misinformation.

The Giant Supercomputer Built to Transform an Entire Country—and Paid For by Ozempic

The world’s latest AI machine is powered by the success of two products: Nvidia’s chips and Novo Nordisk’s weight-loss drugs.

Omada Health Publishes Findings from Consumer Survey of GLP-1 Users, Revealing Majority Discontinue the Drug Before Reaching Their Goal Weight

Omada Health released findings from an attitudinal survey of 1,000 non-Omada members to better understand the needs of consumers taking GLP-1 medications for weight loss. The survey focused on the impact of GLP-1s throughout the patient journey, assessing individuals' feelings and experiences before, during, and after taking the popular weight loss medications.

Donald Tracy, MA on LinkedIn
Let us know what you think!

What would you like to see more of from Pharmaceutical Executive?

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs